Published On: Tue, Sep 13th, 2016

Investment Analysts’ Recent Ratings Updates for Curis (CRIS)

Several analysts have recently updated their ratings and price targets for Curis (NASDAQ: CRIS):

9/12/2016 – Curis was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
9/8/2016 – Curis had its “buy” rating reaffirmed by analysts at FBR & Co.
9/7/2016 – Curis had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $7.00 price target on the stock.
8/31/2016 – Curis was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
8/22/2016 – Curis was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “

Curis Inc. (NASDAQ:CRIS) opened at 1.92 on Tuesday. Curis Inc. has a 1-year low of $1.25 and a 1-year high of $3.18. The firm’s market capitalization is $248.59 million. The company has a 50-day moving average of $1.74 and a 200-day moving average of $1.72.
Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.09). The firm earned $1.70 million during the quarter, compared to analysts’ expectations of $2.05 million. Curis had a negative net margin of 526.72% and a negative return on equity of 65.51%. The business’s revenue for the quarter was down 19.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.06) earnings per share. On average, equities analysts predict that Curis Inc. will post ($0.39) earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/13/investment-analysts-recent-ratings-updates-for-curis-cris.html

In other news, major shareholder Discovery Technologie Aurigene acquired 10,208,333 shares of the firm’s stock in a transaction that occurred on Wednesday, September 7th. The stock was purchased at an average price of $2.40 per share, for a total transaction of $24,499,999.20. Following the completion of the acquisition, the insider now owns 27,328,464 shares in the company, valued at $65,588,313.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 6.09% of the company’s stock.
Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

Receive News & Ratings for Curis Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Curis Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>